Liver disorder

Summary

Liver disorder (MONDO:0005154) is a disease (an umbrella term covering 32 Mondo subtypes) with 3 cohort genes (133 GWAS associations across 93 studies) and 599 clinical trials. Top therapeutic interventions include ribavirin, entecavir anhydrous, and ketotifen.

At a glance

• Umbrella term: 32 Mondo subtypes
• Cohort genes: 3
• GWAS associations: 133
• ClinVar variants: 1
• Clinical trials: 599

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	liver disorder
Mondo ID	MONDO:0005154
EFO	EFO:0001421
MeSH	D008107
DOID	DOID:409
ICD-10-CM	K70-K77
ICD-11	1784240230
NCIT	C3196
SNOMED CT	235856003
UMLS	C4021780
MedGen	893061
Anatomy (UBERON)	UBERON:0002107
Is cancer (heuristic)	no

Also known as: disease of liver · disease or disorder of liver · disorder of liver · hepatic disease · hepatic disorder · liver and intrahepatic bile duct disorder · liver disease · liver disease or disorder · liver disorder

Data availability: 1 ClinVar variant · 133 GWAS associations (93 studies) · 1 GenCC gene-disease record.

Disease family

An umbrella term covering 32 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder

Related subtypes (3): hepatobiliary neoplasm, biliary tract disorder, gallbladder disorder

Subtypes (32): polycystic echinococcosis, autosomal dominant polycystic liver disease, hepatorenal syndrome, hepatitis, hepatic vascular disorder, hepatic porphyria, hepatopulmonary syndrome, fatty liver disease, cirrhosis of liver, drug-induced liver injury, perinatal jaundice due to hepatocellular damage, Aagenaes syndrome, transient familial neonatal hyperbilirubinemia, hyperbiliverdinemia, transient infantile hypertriglyceridemia and hepatosteatosis, idiopathic copper-associated cirrhosis, familial intrahepatic cholestasis, bile duct cyst, nodular regenerative hyperplasia of the liver, hepatoportal sclerosis, primitive portal vein thrombosis, glycogen storage disease due to liver phosphorylase kinase deficiency, liver and intrahepatic bile duct neoplasm, alcoholic liver disease, early-onset familial noncirrhotic portal hypertension, liver failure, fibrotic liver disease, intestinal failure–associated liver disease, liver abscess (disease), membranous obstruction of inferior vena cava, liver disease, severe congenital, cystic fibrosis-related liver disease

Genetics & variants

GWAS landscape

133 GWAS associations across 93 studies. Top hits map to 28 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs738409	1e-323	PNPLA3	C	0.39
rs58542926	4e-119	TM6SF2	C	0.31
rs3747207	4e-78	PNPLA3	G	0.37
chr22:43928847	2e-77		G	0.25
rs6748810	4e-76	ABCG8	A	1.67
rs2001846	3e-46	TRIB1 - TRIB1AL	T	0.11
rs6982502	9e-45	TRIB1AL	C	0.12
rs28601761	5e-44	TRIB1AL	C	0.12
rs780093	2e-38	GCKR	T	0.1
chr2:27752463	8e-37		G	0.11
rs1260326	3e-36	GCKR	T	0.1
rs780094	2e-35	GCKR	T	0.1
rs11977881	1e-33	ABCB4 - ABCB1	T	1.73
rs28929474	7e-33	SERPINA1	C	0.39
rs10107182	9e-33	UBXN2B - CYP7A1	C	1.39
chr19:19259531	1e-30		T	0.24
rs296391	5e-28	LINC01595	C	0.63
rs429358	2e-27	APOE	T	0.14
rs5117	2e-26	APOC1	T	0.1
rs2642438	8e-26	MTARC1	A	0.1
rs1800961	2e-22	HNF4A	C	0.55
rs72623176	9e-22	ABCB11	G	1.74
rs112635299	2e-21	SERPINA2 - SERPINA1	G	0.27
rs71633359	2e-20	KLHL8 - MIR5705	T	0.09
rs28528308	8e-20	KLHL8 - MIR5705	G	0.08
rs28679728	1e-19	KLHL8 - MIR5705	G	0.08
rs10030937	4e-17	TRMT10A	A	0.07
rs9396784	9e-17	SUMO2P13 - FAM8A1	G	1.27
rs738408	1e-16	PNPLA3	C	0.15
rs28497720	2e-16	MTTP	C	0.07

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90476081	Verma A	2024	30,744	401,215	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90473867	UK Biobank Whole-Genome Sequencing Consortium	2025	20,073	438,367	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90473876	UK Biobank Whole-Genome Sequencing Consortium	2025	15,256	443,184	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90476080	Verma A	2024	8,971	107,387	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475246	Verma A	2024	8,715	306,953	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475270	Verma A	2024	8,449	307,219	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476079	Verma A	2024	6,334	50,421	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476082	Verma A	2024	6,136	50,681	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90081521	Backman JD	2021	6,098	381,358	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085507	Backman JD	2021	6,098	381,358	Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	9
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	41

MAF distribution

Bucket	Variants
common (>=0.05)	40
low_freq (0.01-0.05)	1
rare (<0.01)	3
unknown	6

Functional consequences

Consequence	Count
intron_variant	26
unknown	9
missense_variant	8
intergenic_variant	3
non_coding_transcript_exon_variant	2
stop_gained	1
synonymous_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs738409	22	43928847	C>A,G,T	0.224	missense_variant	PNPLA3	1e-323	Tier 1: coding
rs58542926	19	19268740	C>A,T	0.065	stop_gained	TM6SF2	4e-119	Tier 1: coding
rs3747207	22	43928975	G>A,C,T	0.404	intron_variant	PNPLA3	4e-78	Tier 4: intronic/intergenic
chr22:43928847							2e-77	Tier 4: intronic/intergenic
rs6748810	2	43843796	A>G,T	0.05	non_coding_transcript_exon_variant	ABCG8	4e-76	Tier 4: intronic/intergenic
rs2001846	8	125466208	T>A,C,G	0.429	intergenic_variant	TRIB1 - TRIB1AL	3e-46	Tier 4: intronic/intergenic
rs6982502	8	125467120	C>T	0.49	intron_variant	TRIB1AL	9e-45	Tier 4: intronic/intergenic
rs28601761	8	125487789	C>G	0.415	intron_variant	TRIB1AL	5e-44	Tier 4: intronic/intergenic
rs780093	2	27519736	T>A,C,G	0.349	intron_variant	GCKR	2e-38	Tier 4: intronic/intergenic
chr2:27752463				0.413			8e-37	Tier 4: intronic/intergenic
rs1260326	2	27508073	T>A,C,G	0.355	missense_variant	GCKR	3e-36	Tier 1: coding
rs780094	2	27518370	T>A,C,G	0.403	intron_variant	GCKR	2e-35	Tier 4: intronic/intergenic
rs11977881	7	87485697	T>C,G	0.05	intergenic_variant	ABCB4 - ABCB1	1e-33	Tier 4: intronic/intergenic
rs28929474	14	94378610	C>A,G,T	0.05	missense_variant	SERPINA1	7e-33	Tier 1: coding
rs10107182	8	58480178	C>A,T	0.05	intergenic_variant	UBXN2B - CYP7A1	9e-33	Tier 4: intronic/intergenic
chr19:19259531							1e-30	Tier 4: intronic/intergenic
rs296391	19	47865277	C>A,G,T	0.05	non_coding_transcript_exon_variant	LINC01595	5e-28	Tier 4: intronic/intergenic
rs429358	19	44908684	T>C	0.14	missense_variant	APOE	2e-27	Tier 1: coding
rs5117	19	44915533	T>A,C,G	0.223	intron_variant	APOC1	2e-26	Tier 4: intronic/intergenic
rs2642438	1	220796686	A>C,G,T	0.296	missense_variant	MTARC1	8e-26	Tier 1: coding
rs1800961	20	44413724	C>T	0.05	missense_variant	HNF4A	2e-22	Tier 1: coding
rs72623176	2	168977860	G>A	0.05	intron_variant	ABCB11	9e-22	Tier 4: intronic/intergenic
rs112635299	14	94371805	G>A,C,T	0.018	intron_variant	SERPINA2 - SERPINA1	2e-21	Tier 4: intronic/intergenic
rs71633359	4	87262668	T>C	0.299	intron_variant	KLHL8 - MIR5705	2e-20	Tier 4: intronic/intergenic
rs28528308	4	87280348	G>T	0.229	intron_variant	KLHL8 - MIR5705	8e-20	Tier 4: intronic/intergenic
rs28679728	4	87265289	G>A	0.23	intron_variant	KLHL8 - MIR5705	1e-19	Tier 4: intronic/intergenic
rs10030937	4	99552566	A>G	0.256	intron_variant	TRMT10A	4e-17	Tier 4: intronic/intergenic
rs9396784	6	17596908	G>A,T	0.05	intron_variant	SUMO2P13 - FAM8A1	9e-17	Tier 4: intronic/intergenic
rs738408	22	43928850	C>A,G,T	0.223	synonymous_variant	PNPLA3	1e-16	Tier 4: intronic/intergenic
rs28497720	4	99566213	C>A,G,T	0.256	intron_variant	MTTP	2e-16	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 conflicting classifications of pathogenicity

ClinVar	Variant (HGVS)	Gene	Classification	Review
804425	NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter)	MYOM1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 2 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
DECR1	Limited	Autosomal recessive	liver disorder	2

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	1
multi_evidence	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
DECR1	HGNC:2753	ENSG00000104325	Q16698	2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial	gencc
THBS2	HGNC:11786	ENSG00000186340	P35442	Thrombospondin-2	gwas
MYOM1	HGNC:7613	ENSG00000101605	P52179	Myomesin-1	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
DECR1	2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial	Auxiliary enzyme of beta-oxidation.
THBS2	Thrombospondin-2	Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions.
MYOM1	Myomesin-1	Major component of the vertebrate myofibrillar M band.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	9.7×	0.298
Enzyme (other)	1	4.0×	0.345
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
DECR1	Enzyme (other)	yes	1.3.1.124	SDR_fam, NAD(P)-bd_dom_sf
THBS2	Other/Unknown	no		EGF, TSP1_rpt, VWF_dom
MYOM1	Antibody/Immunoglobulin	yes		Ig_sub2, Ig_sub, FN3_dom

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
heart right ventricle	1
left ventricle myocardium	1
right adrenal gland	1
pericardium	1
right coronary artery	1
stromal cell of endometrium	1
gluteal muscle	1
hindlimb stylopod muscle	1
skeletal muscle tissue of rectus abdominis	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
DECR1	296	ubiquitous	marker	left ventricle myocardium, heart right ventricle, right adrenal gland
THBS2	272	ubiquitous	marker	pericardium, right coronary artery, stromal cell of endometrium
MYOM1	215	broad	marker	hindlimb stylopod muscle, skeletal muscle tissue of rectus abdominis, gluteal muscle

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
DECR1	4,079
THBS2	3,405
MYOM1	1,082

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MYOM1	P52179	9
DECR1	Q16698	3
THBS2	P35442	2

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 3 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids	1	951.7×	0.004	DECR1
Defective B3GALTL causes PpS	1	154.3×	0.008	THBS2
O-glycosylation of TSR domain-containing proteins	1	150.3×	0.008	THBS2
Signaling by PDGF	1	126.9×	0.008	THBS2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
extraocular skeletal muscle development	1	936.2×	0.011	MYOM1
obsolete protein kinase A signaling	1	468.1×	0.011	MYOM1
sarcomere organization	1	127.7×	0.017	MYOM1
fatty acid beta-oxidation	1	124.8×	0.017	DECR1
positive regulation of protein secretion	1	114.6×	0.017	MYOM1
positive regulation of synapse assembly	1	81.4×	0.020	THBS2
negative regulation of angiogenesis	1	56.2×	0.023	THBS2
positive regulation of cold-induced thermogenesis	1	54.5×	0.023	DECR1
positive regulation of gene expression	1	12.9×	0.078	MYOM1
cell adhesion	1	12.5×	0.078	THBS2

Therapeutics

Drugs indicated for this disease

3 approved, 12 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cholic Acid	Approved (phase 4)
Givosiran Sodium	Approved (phase 4)
Metreleptin	Approved (phase 4)
Ademetionine	Phase 3 (in late-stage trials)
Avatrombopag	Phase 3 (in late-stage trials)
Biphenyl Dimethyl Dicarboxylate	Phase 3 (in late-stage trials)
Bupivacaine	Phase 3 (in late-stage trials)
Dextrose	Phase 3 (in late-stage trials)
Fentanyl	Phase 3 (in late-stage trials)
Fibrinogen, Human	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Gabexate	Phase 3 (in late-stage trials)
Pioglitazone	Phase 3 (in late-stage trials)
Ursodiol	Phase 3 (in late-stage trials)
Vitamin E	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alemtuzumab, Alisporivir, Amlodipine, Cagrilintide, Cyclosporine, Eltrombopag, Fish Oil, Fish Oil Triglycerides, Icosapent, Maralixibat, Mycophenolate Mofetil, Pentoxifylline, Rafutrombopag, Semaglutide, Sirolimus, Sodium Chloride, Tacrolimus Anhydrous.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3

Druggability breadth: 1 of 3 evidence-associated genes (33%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
DECR1	0	0
THBS2	0	0
MYOM1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
DECR1	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
DECR1	1.3.1.124	2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	2	DECR1, MYOM1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	THBS2

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DECR1	1	—
THBS2	0	—
MYOM1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 599.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	433
PHASE4	49
PHASE1	39
PHASE2	34
PHASE3	22
PHASE2/PHASE3	11
PHASE1/PHASE2	10
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04073290	PHASE4	RECRUITING	Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
NCT04588077	PHASE4	RECRUITING	Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
NCT06144112	PHASE4	NOT_YET_RECRUITING	Fibrinogen Concentrates Versus Cryoprecipitate in Liver Transplant Surgery
NCT07150624	PHASE4	RECRUITING	The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
NCT00148031	PHASE4	COMPLETED	Improving Hepatitis C Treatment in Injection Drug Users
NCT00152607	PHASE4	TERMINATED	Orthotopic Liver Transplantation Using a Living Donor
NCT00155376	PHASE4	UNKNOWN	Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
NCT00206076	PHASE4	COMPLETED	Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation
NCT00222664	PHASE4	COMPLETED	Qidong Hepatitis B Intervention Study
NCT00402402	PHASE4	COMPLETED	Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00564538	PHASE4	UNKNOWN	A Study of Thymoglobulin and Tacrolimus in Liver Transplant
NCT00657124	PHASE4	COMPLETED	Effect of Preoperative Supplementation in Insulin Resistance
NCT00659698	PHASE4	COMPLETED	Effect of an Artificial Pancreas in Patients Undergoing Hepatic Resection
NCT00742326	PHASE4	TERMINATED	Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
NCT00799851	PHASE4	COMPLETED	A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices
NCT00948220	PHASE4	COMPLETED	Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C
NCT01148706	PHASE4	COMPLETED	Effectiveness of ActiSight™ Needle Guidance System in Patients Undergoing CT-Guided Procedures
NCT01195181	PHASE4	COMPLETED	Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
NCT01303549	PHASE4	COMPLETED	Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients
NCT01337440	PHASE4	UNKNOWN	Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases
NCT01429779	PHASE4	UNKNOWN	The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme
NCT01600105	PHASE4	COMPLETED	Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
NCT01650181	PHASE4	COMPLETED	Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
NCT01958190	PHASE4	COMPLETED	Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus
NCT01968395	PHASE4	COMPLETED	Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
NCT02347319	PHASE4	COMPLETED	To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease
NCT02366845	PHASE4	COMPLETED	Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
NCT02489045	PHASE4	COMPLETED	Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
NCT02499185	PHASE4	TERMINATED	Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients
NCT02712775	PHASE4	WITHDRAWN	Minocycline Administration During Human Liver Transplantation
NCT02717949	PHASE4	TERMINATED	Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
NCT02764671	PHASE4	UNKNOWN	Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates
NCT02938013	PHASE4	COMPLETED	deLIVER: Direct Acting Antiviral Effects on the Liver
NCT02949492	PHASE4	TERMINATED	Low-dose IL-2 for Treg Expansion and Tolerance (LITE)
NCT03063866	PHASE4	UNKNOWN	Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease.
NCT03512210	PHASE4	COMPLETED	Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
NCT03522688	PHASE4	UNKNOWN	Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation
NCT03646292	PHASE4	COMPLETED	Antidiabetic Drugs for Steatotic Liver Disease
NCT03652636	PHASE4	COMPLETED	Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RIBAVIRIN	4	7
ENTECAVIR ANHYDROUS	4	3
KETOTIFEN	4	3
LACTULOSE	4	3
SOFOSBUVIR	4	3
ELTROMBOPAG	4	2
LANREOTIDE	4	2
PIOGLITAZONE	4	2
TACROLIMUS ANHYDROUS	4	2
VITAMIN E	4	2
ALCOHOL	4	1
ALEMTUZUMAB	4	1
ANIDULAFUNGIN	4	1
AVATROMBOPAG MALEATE	4	1
CASPOFUNGIN	4	1
COLESEVELAM	4	1
DALTEPARIN SODIUM	4	1
DEXTROSE	4	1
EMPAGLIFLOZIN	4	1
FIBRINOGEN I 125	4	1
GLUCAGON	4	1
HYDROMORPHONE HYDROCHLORIDE	4	1
LEDIPASVIR	4	1
LUSUTROMBOPAG	4	1
METHYLENE BLUE	4	1
METHYLENE BLUE ANHYDROUS	4	1
METHYLENE BLUE CATION	4	1
MORPHINE	4	1
MYCOPHENOLATE MOFETIL	4	1
OCTREOTIDE	4	1